Basic and Clinical Studies of Regulatory Mechanism of GH Secretion
GH分泌调节机制的基础与临床研究
基本信息
- 批准号:62570524
- 负责人:
- 金额:$ 1.34万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for General Scientific Research (C)
- 财政年份:1987
- 资助国家:日本
- 起止时间:1987 至 1988
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Several provocative tests for GH secretion such as insulin tolerance, 1-dopa, arginine infusion and GRF tests have been used in clinical endocrinology. However, the precise mechanisms of GH secretion are not clear in these tests. The mechanisms were, therefore, investigated in this study. Intravenous (iv) injection of 200ug GRF or 0.1U/kg b.w. regular insulin, oral administration of 500mg 1-dopa or infusion of 30g arginine for 30min was preformed 120min, 120min, 90min, or 105nin, respectively, after iv administration of 200ug GRF. The effect of prior subcutaneous administration of SMS201-995, a long acting somatostatin analog, on GH secretion in each provocative test was examined in the same manner. The secretion of GH in response to 200ug GRF was completely inhibited by the prior administration of 200ug GRF, whereas that induced by insulin, 1-dopa or arginine was not affected by the prior sdministration of GRF. The secretion of GH induced by 1-dopa or arginine was completely inhibited by the prior administration of 50ug SMS201-995, and that induced by GRF was completely inhibited by 100ug SMS201-995. The response of GH secretion to insulin was small but significantly preserved even after administration of 100ug SMS201-995. Taken together with the previous reports that 1-dops elevates plasma GRF levels and arginine has no influence on plasma GRF levels, it is suggested that 1-dops stimulates GH secretion probably by suppression of somatostatin release in addition to stimulation of GRF and that arginine stimulates GH secrtion probably by suppression of somatostatin release. It is also suggested that some factor (s) other than GRF and somatostatin is involved in the mechanism whereby insulin stimulates GH secretion since the effect of insulin still exists in the presence of exogenous GRF or somatostatin.
几种刺激GH分泌的试验,如胰岛素耐量试验、1-多巴试验、精氨酸输注试验和GRF试验已用于临床内分泌学。然而,GH分泌的确切机制在这些试验中尚不清楚。因此,在本研究中研究了其机制。静脉注射200 ug GRF或0.1 U/kg b.w.静脉注射GRF 200 μ g后,分别于120 min、120 min、90 min、105 min给予常规胰岛素、1-多巴500 mg口服或精氨酸30 g静滴30 min。以相同的方式检查预先皮下施用SMS 201 -995(一种长效生长抑素类似物)对每次激发试验中GH分泌的影响。预先给予200 μ gGRF可完全抑制200 μ gGRF诱导的GH分泌,而预先给予GRF对胰岛素、1-多巴和精氨酸诱导的GH分泌无影响。预先给予50 μ g SMS 201 -995可完全抑制1-多巴或精氨酸诱导的GH分泌,预先给予100 μ g SMS 201 -995可完全抑制GRF诱导的GH分泌。GH分泌对胰岛素的反应很小,但即使在100 ug SMS 201 -995给药后也显著保持。结合文献报道的1-dops可提高血浆GRF水平,而精氨酸对血浆GRF水平无影响,提示1-dops刺激GH分泌可能除刺激GRF外,还通过抑制生长抑素释放,精氨酸刺激GH分泌可能通过抑制生长抑素释放。提示胰岛素刺激GH分泌的机制可能与GRF和生长抑素以外的其他因素有关,因为在存在外源性GRF或生长抑素的情况下,胰岛素的作用仍然存在。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Shibasaki, T.; Hotta, M.; Yamauchi, N.; Masuda, A.; Imaki, T.; Demura, H.; Ling, N.; Shizume, K.: "Desensitization of rat pituitary somatotrophs to growth hormone-releasing factor occurs in vitro." Endocrinol. Japan.34. 799-807 (1987)
柴崎,T.;
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Shibasaki,T.,et al.: "Neuroendocrine control of the hypothalamo-pituitary system.Taniguchi Sympsia on Brain Sciences" Japan Scientific Societies Press, 151-157 (1988)
Shibasaki,T.,et al.:“下丘脑-垂体系统的神经内分泌控制。谷口脑科学研讨会”日本科学会出版社,151-157(1988)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Masuda, A.; Shibasaki, T.; Hotta, M.; Suematsu, H.; Shizume, K.: "Study on the mechanism of abnormal growth hormone (GH) secretion in anorexia nervosa: no evidence of involvement of a low somatomedin-C level in the abnormal GH secretion." J. Endocrinol. I
增田,A.;
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Shibasaki, T.; Masuda, A.; Hotta, M.; Yamauchi, N.; Hizuka, N.; Takano, K.; Demura, H.; Shizume, K.: "Effects of ingestion of glucose on GH and TSH secretion: Evidence for stimu-lation of somatostatin release from the hypothalamus byu acute hyperglycemia
柴崎,T.;
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHIBASAKI Tamotsu其他文献
SHIBASAKI Tamotsu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHIBASAKI Tamotsu', 18)}}的其他基金
The analysis of epigenetic changes in GH-IGF-1 axis of small for gestational age rats
小于胎龄大鼠GH-IGF-1轴表观遗传变化分析
- 批准号:
23659480 - 财政年份:2011
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Study on the function s of growth hormone secretagogue receptor
生长激素促分泌受体的功能研究
- 批准号:
14571077 - 财政年份:2002
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
CLINICAL TRIAL: 2MG DOSE OF TH9507, A GROWTH HORMONE RELEASING FACTOR ANALOG IN
临床试验:2MG 剂量的 TH9507,一种生长激素释放因子类似物
- 批准号:
7731303 - 财政年份:2008
- 资助金额:
$ 1.34万 - 项目类别:
HUMAN GROWTH HORMONE RELEASING FACTOR IN LONG TERM TREATMENT OF CHILD
儿童长期治疗中的人类生长激素释放因子
- 批准号:
6308580 - 财政年份:1999
- 资助金额:
$ 1.34万 - 项目类别:
ROLE OF GROWTH HORMONE RELEASING FACTOR IN SHORT STATURE
生长激素释放因子在身材矮小中的作用
- 批准号:
6309711 - 财政年份:1999
- 资助金额:
$ 1.34万 - 项目类别:
ROLE OF GROWTH HORMONE RELEASING FACTOR IN SHORT STATURE
生长激素释放因子在身材矮小中的作用
- 批准号:
6122549 - 财政年份:1998
- 资助金额:
$ 1.34万 - 项目类别:
ROLE OF GROWTH HORMONE RELEASING FACTOR IN SHORT STATURE
生长激素释放因子在身材矮小中的作用
- 批准号:
6282584 - 财政年份:1997
- 资助金额:
$ 1.34万 - 项目类别:
ROLE OF GROWTH HORMONE RELEASING FACTOR IN SHORT STATURE
生长激素释放因子在身材矮小中的作用
- 批准号:
6253580 - 财政年份:1997
- 资助金额:
$ 1.34万 - 项目类别:














{{item.name}}会员




